Voyager Therapeutics, Inc. Common Stock (VYGR) Stock Price

VYGRStock

$3.48+0.29%52W

Market Cap$214.43M

P/E—

PEG Ratio—

Div yield—

Beta1.25

VYGR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.25%

Price vs S&P 500 (4W)10.11%

VGM Score45.58

Book Value / Share (Quarterly)$2.52

P/TBV (Annual)5.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.43%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)-24.43%

Net Profit Margin (TTM)-312.63%

EPS (TTM)$-1.81

10-Day Avg Trading Volume0.47M

EPS Excl Extra (TTM)$-1.81

Revenue Growth (5Y)-25.08%

EPS (Annual)$-2.04

ROI (Annual)-61.06%

Net Profit Margin (5Y Avg)-125.73%

Cash / Share (Quarterly)$1.90

Revenue Growth QoQ (YoY)-39.13%

ROA (Last FY)-47.46%

Revenue Growth TTM (YoY)-19.07%

EBITD / Share (TTM)$-1.91

ROE (5Y Avg)-36.05%

Operating Margin (TTM)-340.08%

Cash Flow / Share (Annual)$-2.29

P/B Ratio1.25x

P/B Ratio (Quarterly)1.37x

Net Income / Employee (Annual)$-849,100

EV / Revenue (TTM)4.57x

Net Interest Coverage (TTM)-177.00x

ROA (TTM)-45.00%

EV / EBITDA (TTM)11.32x

EPS Incl Extra (Annual)$-2.04

Current Ratio (Annual)7.64x

Quick Ratio (Quarterly)7.16x

3-Month Avg Trading Volume0.58M

52-Week Price Return0.29%

Revenue / Employee (TTM)$244,400

Tangible BV / Share (Quarterly)$4.01

P/S Ratio (Annual)4.79x

Asset Turnover (Annual)0.16x

52-Week High$5.55

Operating Margin (5Y Avg)-140.57%

EPS Excl Extra (Annual)$-2.04

CapEx CAGR (5Y)-26.50%

Tangible BV CAGR (5Y)-15.13%

26-Week Price Return2.99%

Quick Ratio (Annual)7.60x

13-Week Price Return-6.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.51x

Enterprise Value$157.58M

Revenue / Share Growth (5Y)-31.58%

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)-4.25%

Revenue / Employee (Annual)$286,300

Pretax Margin (Annual)-296.17%

Cash / Share (Annual)$3.33

3-Month Return Std Dev47.58%

Net Income / Employee (TTM)$-764,000

ROE (Last FY)-61.06%

EPS Basic Excl Extra (Annual)$-2.04

P/FCF (TTM)3.41x

Receivables Turnover (TTM)12.14x

EV / Free Cash Flow (TTM)0.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.81

Receivables Turnover (Annual)19.73x

ROI (TTM)-57.92%

P/S Ratio (TTM)5.61x

Pretax Margin (5Y Avg)-125.38%

Revenue / Share (Annual)$0.69

Tangible BV / Share (Annual)$1.53

Price vs S&P 500 (52W)-18.02%

Year-to-Date Return-12.47%

5-Day Price Return4.24%

EPS Normalized (Annual)$-2.04

ROA (5Y Avg)-18.43%

Net Profit Margin (Annual)-296.53%

Month-to-Date Return13.53%

Cash Flow / Share (TTM)$1.34

EBITD / Share (Annual)$-2.18

Operating Margin (Annual)-326.56%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-36.05%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.81

P/TBV (Quarterly)1.71x

P/B Ratio (Annual)1.11x

Pretax Margin (TTM)-312.26%

Book Value / Share (Annual)$3.32

Price vs S&P 500 (13W)-9.32%

Beta1.25x

P/FCF (Annual)2.59x

Revenue / Share (TTM)$0.57

ROE (TTM)-57.92%

52-Week Low$2.94

vGradeB

gGradeF

mGradeC

vgmGradeC

VYGR Earnings Surprise History

Q2 25-0.57est. -0.52

Q3 25-0.47est. -0.52

Q4 25-0.47est. -0.51

Q1 26-0.47est. -0.53

Q2 26-0.40est. -0.51

VYGR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.39

4.41

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
VYGRVoyager Therapeutics, Inc. Common Stock	B	F	C	$3.48
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Voyager Therapeutics, Inc. Common Stock

Voyager Therapeutics is a gene therapy company developing AAV-based treatments for severe neurological diseases. The company's proprietary TRACER platform enables the engineering, optimization, and delivery of therapies designed to achieve durable efficacy following single-dose administration. Its pipeline includes programs targeting tau-related neurodegeneration, SOD1 overexpression disorders, and Friedreich's ataxia.